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MDS) and approximately 40% were in ﬁrst complete remis-
sion or ﬁrst chronic phase. 93% of transplantations used
donors younger than 50 (median 35.8, range 18-61). The
majority of patients received myeloablative preparative
regimens (88%) and bone marrow grafts (62%). All patients
received calcineurin inhibitor containing GVHD prophylaxis
and 20% received in vivo T cell depletion. We identiﬁed three
donor characteristics associated with overall survival; donor
age, high resolution donor-recipient HLA-match and ABO
blood group match. Risk adjusted 5-year survival rates were
37%, 33% and 29% with donors aged 18-32, 33-50, and >50
years, respectively (p<0.0001). Corresponding hazard ratios
were 1.13 (p¼0.0004) for donors aged 33e50 years and 1.29
(p<0.001) for donors >50 years compared with donors aged
18 e 32 years. Mortality risks were higher with one (HR 1.24,
P < .0001) and two (HR 1.62, P < .0001) HLA-mismatches
compared with HLA-matched transplants and minor (HR
1.10, P ¼ .002) or major (HR 1.13, P ¼ .001) ABO blood group
mismatch compared with ABO-matched transplants. A sub-
analysis investigated the possibility that the associationwith
donor age may be due to underlying genetic disparity
between donor and recipient. That is, recipients with rare
HLA genotypes tend to have fewer matched donors to choose
from and thus more likely to receive a graft from an older
donor. Recipient genotypes were assigned to quartiles using
frequency data from 4 million NMDP donors as a reference.
The lowest frequency quartile was associated with donors
older than 50 (p<0.0001) and higher rates of HLA mis-
matching (p<0.001) but no association was found between
genotype frequency and overall mortality. Acute GVHD risks
were associated with donor age and HLA match and, donor
parity, the only donor characteristic associated with chronic
GVHD (table). In summary, the data recommend the
consideration of donor age and ABO blood group match to
maximize survival when selecting among comparably HLA-
matched adult unrelated stem cell donors for treatment of
a hematologic malignancy.68
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Background: Umbilical cord blood transplantation (UCBT) is
associated with delay in platelet recovery. However, the
underlying factors inﬂuencing this delayed recovery remain
poorly understood. With the aim of identifying factors that
inﬂuence platelet engraftment, we retrospectively analyzed
data from 68 consecutive myeloablative UCBT recipients
transplanted between April 2006 and March 2012.
Methods: Forty-two (62%) patients received high-dose TBI
(1320 cGy), cyclophosphamide and ﬂudarabine (FLU); while
26 (38%) received Treosulfan, FLU, and a single fraction of
200cGy TBI. Graft-versus-host-disease (GVHD) prophylaxis
consisted of cyclosporine and mycophenolate mofetil.
Platelet recovery was deﬁned as the ﬁrst day of a platelet
count 20 and 50 x 109/L without transfusion for 7 days.
Cumulative incidence (CI) curves were used to estimate the
probabilities of platelet engraftment in the ﬁrst 100 days
post- transplant. A proportional hazards regression model
was used to evaluate the association between CD34+ celldose and platelet engraftment. Factors considered as
potential predictors or confounders included age at trans-
plant, sex, race, body mass index (BMI), disease risk, CMV
seropositivity, presence of minimal residual disease at
transplant (MRD), number of UCB units infused, acute GVHD,
total nucleated cells (TNC) and CD34+ cells.
Results:Median age and BMIwere 36 years (range,1-63) and
26 kg/m2 (range, 16-41), respectively. The majority of
patients (88%) received 2 cord blood units (n¼60). Twenty-
seven (40%) hadMRD and 46 (68%) were CMV seropositive at
time of transplant. Median total infused cell doses were: 3.9
x 107 TNC/kg (range: 2.2-11.2) and 0.25 x 106 CD34+ cells/kg
(range: 0.09 e 1.46). The 100-day CI of platelet engraftment
was 65% (95% CI: 53-76%) for platelets 20 109/L and 59%
(95% CI: 47-71%) for platelets 50 109/L. In univariate anal-
ysis higher CD34+ infused dose was signiﬁcantly associated
with platelet engraftment [HR¼1.4 (95% CI: 1.0-1.9, P ¼ .03)].
Furthermore, platelet engraftment was suggestively slower
among patients with higher BMI [HR¼0.9 (95% CI: 0.9-1.0, P
¼ .06)] while presence of aGVHD grade III-IV was associated
with higher rate of engraftment [HR¼2.1 (95% CI: 0.8-5.9, P¼
.07)]. No signiﬁcant associations were found between all the
others factors analyzed and platelet recovery.In multivari-
able analysis the association between larger CD34+ dose and
higher rate of engraftment remained statistically signiﬁcant
[HR¼1.9 (95% CI: 1.3-2.8, P < .001]. In addition, CMV sero-
positivity [HR¼0.4 (95% CI: .0.2-0.9, P ¼ .02)] became
signiﬁcantly associated with a slower rate of engraftment.
Conclusions: These results indicate that the infused CD34+
dose is a strong independent predictor of platelet engraft-
ment. Furthermore we should expect an earlier sustained
platelet recovery among CMV seronegative patients.IMMUNE RECONSTITUTION ORAL
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Low dose interleukin-2 (IL-2) can increase regulatory T
cells (Treg) and has therapeutic beneﬁt in steroid refractory
cGVHD. To further deﬁne immunological changes underlying
the response to IL-2 and to determine tolerability, we per-
formed phenotypic characterization and functional analysis
of Treg and natural killer (NK) cells in individuals given IL-2.
Six healthy volunteers received subcutaneous ultra low dose
IL-2 (0.2MIU/m2/day) for 5 days without signiﬁcant side
effects. Two patients with steroid and calcineurin-refractory
cGVHD received the same dose of IL-2 daily for 4 or 8 weeks,
after HLA identical myeloablative stem cell transplant (SCT)
for AML. Patient 1 (50 year old male, 3 yr post SCT) had skin
and fascial GVHD affecting the lower limbs. Patient 2 (44 year
old female, 2 yr post SCT) had upper gastrointestinal cGVHD.
Both patients had a prompt and durable partial response by
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withdrawn in patient 1 and reduced (budesdonide from 15 to
5mg) in patient 2. Mononuclear cells were analyzed by ﬂow
cytometry before and after IL-2 in patients and healthy
donors. Treg subsets were determined within the CD4+ T cell
population to identify thymus-derived natural Treg (nTreg)
and induced Treg (iTreg). NK cell subsets were determined
within CD56+CD3- population to identify CD56bright,
CD56dimNKG2A+KIR-, and CD56dim KIR+CD57+ NK cells.
Functional analysis was performed by isolating Treg
(CD3+CD4+CD25hiCD127dim), conventional T cells (Tcon:
CD3+CD4+CD25loCD127hi) and NK cells (CD3-CD56+). Treg
function was measured by suppression of CD154 expression
on Tcon stimulated with CD3/CD28 beads. NK cell function
was measured by K562 killing. Healthy volunteers showed
a signiﬁcant increase in both nTreg and iTreg by 2-3 fold
(p¼0.0003) and CD56bright NK cells by 1.2-1.8 fold in 7 days
after the initial dose of IL-2 (p¼0.02). In patients, the fraction
of nTreg increased above baseline by 1.2-1.4 fold while iTreg
decreased. NK cells showed marked expansion of CD56bright
NK cells within 2 weeks of treatment, with no change in
CD56dimNKG2A+KIR-, and CD56dimKIR+CD57+ NK cells.
Functional assays demonstrated increased Treg suppression
of autologous Tcon and NK cell killing of K562 after IL-2
treatment in both patients. These ﬁndings indicate that ultra
low dose IL-2 causes expansion of natural Treg and NK cells
resulting in greater suppressive activity and K562 killing
activity correlating with an improvement in cGVHD for
steroid refractory patients.
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The favorable outcome of umbilical cord blood trans-
plantation (UCBT) is compromised by prolonged time to
engraftment, delayed immunologic reconstitution and late
memory T cell skewing. Studies in zebraﬁsh and mice have
shown that the prostaglandin compound, 16,16 dimethyl
prostaglandin E2 (PGE2) increases HSC engraftment. We
performed a Phase Ib clinical trial of double UCBT (dUCBT)
using one untreated and one ex vivo PGE2-treated UCB unit
to determine safety and engraftment. 12 subjects with
hematologic malignancies were enrolled. The PGE2-UCB was
the dominant source of hematopoiesis in 10 of 12 subjects
with full T cell chimerism detected as early as 13 days. In UCB
T cells, PGE2 mediated increase of intracellular cAMP, acti-
vation of PKA and modulated the Wnt/b-catenin pathway as
determined by upregulation of b-catenin and expression of
Wnt target genes Lef1, Tcf7 and Runx1. PGE2 inhibited
proliferation of UCB T cells in response to stimulation via
CD3/CD28 and resulted in high expression of IL-7 receptor
(CD127). Assessment of T cell reconstitution indicated that
during the ﬁrst year, the numbers of total T cells (CD3+), CD4+
and CD8+ T subsets remained signiﬁcantly lower (p¼0.036)
in PGE2-UCBT recipients compared to dUCBT recipients
without PGE2. To examine whether PGE2-mediated Wnt/b-
catenin imprinting might be evident in PGE2-UCBT recipi-
ents, we examined expression of the Wnt/b-catenin target
Eomes, a transcription factor that links the long-term
memory CD8+ T cells to effector potency and protective
immunity. Expression of Eomes was signiﬁcantly elevated in
PBMCs of PGE2-UCBT recipients compared to controls.
Consistent with the role of Wnt/b-catenin to maintain
a central memory/stem cell memory CD8+ phenotype, there
was an increased fraction of CD8+CD62L+ cells in recipients of
PGE2-UCBT in contrast to the late memory T cell skewing in
dUCBT recipients without PGE2. Moreover, PGE2-UCBT
recipients displayed potent antiviral immunity resulting in
a reduced incidence of CMV viremia and no EBV-mediated
posttransplant lymphoproliferative disorder. Our ﬁndings
indicate that PGE2-UCB treatment induces Wnt-mediated
gene programming and might favor the generation of long-
lived memory CD8+ T cells.71
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Graft-versus-host disease (GVHD) is a detrimental
complication of allogeneic hematopoietic cell trans-
plantation (HCT) associatedwith impaired quality-of-life and
decreased overall survival. Methods for predicting GVHD
may enable use of pre-emptive therapeutic maneuvers to
prevent or diminish clinical GVHD symptoms. Studies of
GVHD in murine allograft models have shown that GVH
reactions are associated with structural and functional
derangements of lymphoid tissues, including lymph nodes,
spleen, thymus, and bone marrow. Because these organs
